IRADIMED (IRMD) director sells 3,000 shares in open-market trades

Q: How many IRADIMED (IRMD) shares did the director sell and at what price?

The director sold a combined 3,000 shares of IRADIMED Common Stock. The filing notes that the transactions were executed at $95.00 per share . This reflects two separate open-market sale entries that together sum to this aggregate share amount at the same price level.

Q: What type of insider transaction is disclosed for IRADIMED (IRMD)?

The filing discloses open-market sales of IRADIMED Common Stock coded as “S” transactions. These are non-derivative trades where the director sold existing shares directly into the market, rather than exercising options or converting derivatives into stock in this particular report.

Q: Does the IRADIMED (IRMD) Form 4 mention any derivative securities or options?

This Form 4 focuses on non-derivative Common Stock transactions and does not list any current derivative positions in its derivative summary. The reported activity consists solely of open-market sales of existing shares, without new option exercises or other derivative conversions.

Filing Impact

(Moderate)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

IRADIMED CORP director Hilda Frederique Scharen-Guivel sold 3,000 shares of Common Stock in open-market transactions at $95.00 per share. The sales occurred on June 4, 2026. Footnotes state that the shares she continues to hold were acquired through the vesting and settlement of restricted stock units granted for her board service.

Insider Trade Summary

Net Seller: 3,000 shares ($285,000)

Net Sell 2 txns

Insider Scharen-Guivel Hilda Frederique

Role null

Sold 3,000 shs ($285K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,766	$95.00	$168K
Sale	Common Stock	1,234	$95.00	$117K

Holdings After Transaction: Common Stock — 6,832 shares (Direct, null)

Footnotes (1)

This transaction was executed at $95.00. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. The shares reported as beneficially owned following the reported transaction consist of shares acquired upon the vesting and settlement of restricted stock units granted in connection with the reporting person's service as a director. Such shares were acquired in multiple vesting transactions occurring on various dates.

Key Figures

Shares sold: 3,000 shares Sale price: $95.00 per share Number of sale transactions: 2 transactions +1 more

4 metrics

Shares sold 3,000 shares Total Common Stock sold by director on June 4, 2026

Sale price $95.00 per share Price at which the reported transactions were executed

Number of sale transactions 2 transactions Open-market sales of Common Stock coded as S

Net share change -3,000 shares Net buy/sell shares from this Form 4 transaction set

Key Terms

open-market sale, restricted stock units, beneficially owned, non-derivative

4 terms

open-market sale financial

"transaction_action: "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

restricted stock units financial

"shares acquired upon the vesting and settlement of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

beneficially owned financial

"The shares reported as beneficially owned following the reported transaction consist of shares acquired"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

non-derivative financial

"transaction_type: "non-derivative" for the Common Stock transactions"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/04/2026 - 04:21 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Scharen-Guivel Hilda Frederique

(Last)

(First)

(Middle)

C/O IRADIMED CORPORATION

12705 INGENUITY DRIVE

(Street)

ORLANDO

FLORIDA

32826

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
IRADIMED CORP [ IRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/04/2026		S		1,766	D	$95⁽¹⁾	6,832⁽²⁾	D
Common Stock	06/04/2026		S		1,234	D	$95⁽¹⁾	5,598⁽²⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. This transaction was executed at $95.00. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

2. The shares reported as beneficially owned following the reported transaction consist of shares acquired upon the vesting and settlement of restricted stock units granted in connection with the reporting person's service as a director. Such shares were acquired in multiple vesting transactions occurring on various dates.

Remarks:

	/s/ Hilda Scharen-Guivel	06/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did IRADIMED (IRMD) report in this Form 4?

IRADIMED reported that director Hilda Frederique Scharen-Guivel executed open-market sales of company Common Stock. The filing shows she sold a total of 3,000 shares in separate transactions on June 4, 2026 at a reported price of $95.00 per share.

How many IRADIMED (IRMD) shares did the director sell and at what price?

The director sold a combined 3,000 shares of IRADIMED Common Stock. The filing notes that the transactions were executed at $95.00 per share. This reflects two separate open-market sale entries that together sum to this aggregate share amount at the same price level.

What type of insider transaction is disclosed for IRADIMED (IRMD)?

The filing discloses open-market sales of IRADIMED Common Stock coded as “S” transactions. These are non-derivative trades where the director sold existing shares directly into the market, rather than exercising options or converting derivatives into stock in this particular report.

Did the IRADIMED (IRMD) director acquire these shares through compensation?

The filing explains that the shares reported as beneficially owned after the transactions were acquired through vesting and settlement of restricted stock units. Those RSUs were granted in connection with the director’s service on IRADIMED’s board and vested on various historical dates.

Does the IRADIMED (IRMD) Form 4 mention any derivative securities or options?

This Form 4 focuses on non-derivative Common Stock transactions and does not list any current derivative positions in its derivative summary. The reported activity consists solely of open-market sales of existing shares, without new option exercises or other derivative conversions.